1. Takahashi M, Mori N, Bito S. Multi-institution case-control and cohort study of risk factors for the development and mortality of Clostridium difficile infections in Japan. BMJ Open 2014; 34:1-9. https://doi.org/10.1136/bmjopen-2014-005665;
2. CrobachMJ, Planche T, Eckert C, et al. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect 2016; 22 Suppl 4:S63-81. https://doi.org/10.1016/j.cmi.2016.03.010;
3. Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infec 2006; 12:2-18. https://doi.org/10.1111/j.1469-0691.2006.01580.x;
4. Gupta A, Cifu AS, Khanna S. Diagnosis and Treatment of Clostridium difficile Infection. JAMA 2018 11; 320:1031-3. https://doi.org/10.1001/jama.2018.12194;
5. Vanpoucke H, Baere T, Claeys G, et al. Evaluation of six commercial assays for the rapid detection of Clostridium difficile toxin and/or antigen in stool specimens. Clin Microbiol Infec 2001; 2: 55-64. https://doi.org/10.1046/j.1469-0691.2001.00141.x;